Mexico

HPV INFORMATION CENTRE

Human Papillomavirus and Related Cancers, Fact Sheet 2023 (2023-03-10)

I. Key data on HPV and HPV-related cancers



Mexico has a population of 49.6 million women ages 15 years and older who are at risk of developing cervical cancer. Current estimates indicate that every year 9439 women are diagnosed with cervical cancer and 4335 die from the disease. Cervical cancer ranks as the 2nd most frequent cancer among women in Mexico and the 3rd most frequent cancer

among women between 15 and 44 years of age. About 4.1% of women in the general population are estimated to harbour cervical HPV-16/18 infection at a given time, and 65.0% of invasive cervical cancers are attributed to HPVs 16 or 18.

Table 1. Crude incidence rates of HPV-related cancers

	Male	Female
Cervical cancer	-	14.3
Anal cancer	0.20	0.28
Vulva cancer	-	0.83
Vaginal cancer	-	0.35
Penile cancer	1.10	-
Oropharyngeal cancer	0.36	0.16
Oral cavity cancer	1.00	1.32
Laryngeal cancer	1.35	0.27


Table 2. Burden of cervical cancer

	Incidence	Mortality
Annual number of new cases/deaths	9439	4335
Crude rate	14.3	6.58
Age-standarized rate	12.6	5.74
Cumulative risk 0-74 years (%)	1.29	0.63
Ranking of cervical cancer (all years)	2nd	3rd
Ranking of cervical cancer (15-44 years)	3rd	2nd

Table 3. Burden of cervical HPV infection Mexico

	No. Tested	% (95% CI)	
HPV 16/18 prevalence:			
Normal cytology	8089	4.1 (3.7-4.6)	
Low-grade cervical lesions	1291	15.3 (13.5-17.4)	
High-grade cervical lesions	247	37.7 (31.8-43.8)	
Cervical cancer	2361	65.0 (63.1-66.9)	

Figure 1. Comparison of the ten most frequent HPV oncogenic types in Mexico among women with and without cervical lesions



Mexico



Human Papillomavirus and Related Cancers, Fact Sheet 2023 (2023-03-10)

II. Complementary data on cervical cancer prevention

Table 4. Factors contributing to cervical cancer (cofactors)

Smoking prevalence (%) [95% UI], women	7 [5.4-8.6]	
Total fertility rate (live births per women)	2.1	
Hormonal contraception use (%)	3	
HIV prevalence (%) [95% UI] (15-49 years)<0.1 [<0.1 -<0.1]		

Table 5 Sexual behaviour

-
-
-
-
•


Table 6. HPV vaccine introduction

lable 6. HPV vaccine introduction	
Females	
HPV vaccination programme	Introduced
Year of introduction	2012
Year of estimation	2021
HPV coverage – first dose (%)	1
HPV coverage – last dose (%)	1
Males	
HPV vaccination programme	Not Available/Not Introduced
Year of introduction	-
Year of estimation	-
HPV coverage – first dose (%)	-
HPV coverage – last dose (%)	<u>-</u>

Table 7. Cervical screening practices and recommendations

Existence of official national rec-	Yes
ommendations	
Starting year of recommendations	2013
Active invitation to screening	No
Screening ages (years), pri-	25-64 (cytology, 3
mary screening test used, and	years); 35-64 (HPV
screening interval or frequency of	test, 5 years)
screenings	

Figure 2. Estimated coverage of cervical cancer screening in Mexico*



^{*} Estimated coverage and 95% confidence interval in 2019

Contact information:

ICO/IARC HPV Information Centre

Institut Català d'Oncologia

Avda. Gran Via de l'Hospitalet, 199-203

08908 L'Hospitalet de Llobregat (Barcelona, Spain)

info@hpvcentre.net

www.hpvcentre.net